Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Trial Profile

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs ACTR 087 (Primary) ; Rituximab
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 01 Nov 2017 According to an Unum Therapeutics media release, company is currently enrolling and treating patients in Cohort 2.
    • 01 Nov 2017 According to an Unum Therapeutics media release, initial data will be presented at the 59th ASH Annual Meeting.
    • 06 Dec 2016 Trial design presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top